VERTEX PHARMACEUTICALS INC / MA Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $2.71 billion for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-12-31 was $583.23M, a 61.76% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-09-30 was $57.52M, a 55.22% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-06-30 was $267.43M, a 29.66% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-03-31 was $268.63M, a 18.18% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was $2.71B, a 130.42% increase from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was $1.18B, a 43.62% decline from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was $2.09B, a 2177.63% increase from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA net income (loss), including portion attributable to noncontrolling interest for fiscal 2017 was $91.64M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2020-12-31 | $2.71B 10-K · filed 2021-02-11 | |||
| 2019-12-31 | $583.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $640.75M derived: sum of 2 quarters · filed 2021-02-11 | $908.18M derived: sum of 3 quarters · filed 2021-02-11 | $1.18B 10-K · filed 2021-02-11 |
| 2019-09-30 | $57.52M 10-Q · filed 2019-10-31 | $324.94M derived: sum of 2 quarters · filed 2019-10-31 | $593.58M 10-Q · filed 2019-10-31 | $2.12B derived: sum of 4 quarters · filed 2020-02-13 |
| 2019-06-30 | $267.43M 10-Q · filed 2019-08-01 | $536.06M 10-Q · filed 2019-08-01 | $2.06B derived: sum of 3 quarters · filed 2020-02-13 | $2.19B derived: sum of 4 quarters · filed 2020-02-13 |
| 2019-03-31 | $268.63M 10-Q · filed 2019-05-01 | $1.79B derived: sum of 2 quarters · filed 2020-02-13 | $1.92B derived: sum of 3 quarters · filed 2020-02-13 | $2.13B derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-12-31 | $1.53B 10-K · filed 2020-02-13 | $1.65B derived: sum of 2 quarters · filed 2020-02-13 | $1.86B derived: sum of 3 quarters · filed 2020-02-13 | $2.09B 10-K · filed 2021-02-11 |
| 2018-09-30 | $128.46M 10-K · filed 2020-02-13 | $334.71M derived: sum of 2 quarters · filed 2020-02-13 | $562.01M 10-Q · filed 2019-10-31 | $664.19M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $206.25M 10-K · filed 2020-02-13 | $433.55M 10-Q · filed 2019-08-01 | $535.74M derived: sum of 3 quarters · filed 2020-02-13 | $244.47M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $227.30M 10-K · filed 2020-02-13 | $329.49M derived: sum of 2 quarters · filed 2020-02-13 | $38.22M derived: sum of 3 quarters · filed 2020-02-13 | $69.39M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $102.19M 10-K · filed 2019-02-13 | -$189.08M derived: sum of 2 quarters · filed 2019-02-13 | -$157.91M derived: sum of 3 quarters · filed 2019-02-13 | $91.64M 10-K · filed 2020-02-13 |
| 2017-09-30 | -$291.27M 10-K · filed 2019-02-13 | -$260.10M derived: sum of 2 quarters · filed 2019-02-13 | -$10.55M 10-Q · filed 2018-10-25 | $17.21M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | $31.17M 10-K · filed 2019-02-13 | $280.72M 10-Q · filed 2018-07-26 | $308.48M derived: sum of 3 quarters · filed 2019-02-13 | $268.94M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | $249.55M 10-K · filed 2019-02-13 | $277.31M derived: sum of 2 quarters · filed 2019-02-13 | $237.77M derived: sum of 3 quarters · filed 2019-02-13 | $201.62M derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $27.76M 10-K · filed 2018-02-15 | -$11.78M derived: sum of 2 quarters · filed 2018-02-15 | -$47.93M derived: sum of 3 quarters · filed 2018-02-15 | -$84.03M 10-K · filed 2019-02-13 |
| 2016-09-30 | -$39.54M 10-K · filed 2018-02-15 | -$75.69M derived: sum of 2 quarters · filed 2018-02-15 | -$111.79M 10-Q · filed 2017-10-30 | -$186.46M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | -$36.15M 10-K · filed 2018-02-15 | -$72.25M 10-Q · filed 2017-07-28 | -$146.92M derived: sum of 3 quarters · filed 2018-02-15 | -$240.74M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | -$36.10M 10-K · filed 2018-02-15 | -$110.77M derived: sum of 2 quarters · filed 2018-02-15 | -$204.59M derived: sum of 3 quarters · filed 2018-02-15 | -$425.58M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | -$74.67M 10-K · filed 2017-02-23 | -$168.49M derived: sum of 2 quarters · filed 2017-02-23 | -$389.48M derived: sum of 3 quarters · filed 2017-02-23 | -$588.18M 10-K · filed 2018-02-15 |
| 2015-09-30 | -$93.82M 10-K · filed 2017-02-23 | -$314.81M derived: sum of 2 quarters · filed 2017-02-23 | -$513.51M 10-Q · filed 2016-10-31 | -$694.36M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | -$220.99M 10-K · filed 2017-02-23 | -$419.70M 10-Q · filed 2016-08-01 | -$600.54M derived: sum of 3 quarters · filed 2017-02-23 | -$770.60M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | -$198.70M 10-K · filed 2017-02-23 | -$379.55M derived: sum of 2 quarters · filed 2017-02-23 | -$549.61M derived: sum of 3 quarters · filed 2017-02-23 | -$708.99M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | -$180.85M 10-K · filed 2016-02-16 | -$350.91M derived: sum of 2 quarters · filed 2016-02-16 | -$510.29M derived: sum of 3 quarters · filed 2016-02-16 | -$742.75M 10-K · filed 2017-02-23 |
| 2014-09-30 | -$170.06M 10-K · filed 2016-02-16 | -$329.44M derived: sum of 2 quarters · filed 2016-02-16 | -$561.90M 10-Q · filed 2015-10-30 | -$746.45M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | -$159.38M 10-K · filed 2016-02-16 | -$391.84M 10-Q · filed 2015-08-04 | -$576.39M derived: sum of 3 quarters · filed 2016-02-16 | -$705.05M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | -$232.46M 10-K · filed 2016-02-16 | -$417.01M derived: sum of 2 quarters · filed 2016-02-16 | -$545.67M derived: sum of 3 quarters · filed 2016-02-16 | -$607.38M derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | -$184.55M 10-K · filed 2015-02-13 | -$313.21M derived: sum of 2 quarters · filed 2015-02-13 | -$374.92M derived: sum of 3 quarters · filed 2015-02-13 | -$687.55M 10-K · filed 2016-02-16 |
| 2013-09-30 | -$128.66M 10-K · filed 2015-02-13 | -$190.37M derived: sum of 2 quarters · filed 2015-02-13 | -$503.00M 10-Q · filed 2014-11-06 | -$581.08M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | -$61.71M 10-K · filed 2015-02-13 | -$374.34M 10-Q · filed 2014-07-31 | -$452.42M derived: sum of 3 quarters · filed 2015-02-13 | -$478.88M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | -$312.63M 10-K · filed 2015-02-13 | -$390.70M derived: sum of 2 quarters · filed 2015-02-13 | -$417.17M derived: sum of 3 quarters · filed 2015-02-13 | -$451.64M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | -$78.08M 10-K · filed 2014-02-11 | -$104.54M derived: sum of 2 quarters · filed 2014-02-11 | -$139.01M derived: sum of 3 quarters · filed 2014-02-11 | -$51.13M 10-K · filed 2015-02-13 |
| 2012-09-30 | -$26.47M 10-K · filed 2014-02-11 | -$60.94M derived: sum of 2 quarters · filed 2014-02-11 | $26.94M 10-Q · filed 2013-11-07 | $215.08M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | -$34.47M 10-K · filed 2014-02-11 | $53.41M 10-Q · filed 2013-08-02 | $241.55M derived: sum of 3 quarters · filed 2014-02-11 | $470.00M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $87.88M 10-K · filed 2014-02-11 | $276.02M derived: sum of 2 quarters · filed 2014-02-11 | $504.47M derived: sum of 3 quarters · filed 2014-02-11 | $305.15M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $188.14M 10-K · filed 2013-03-01 | $416.59M derived: sum of 2 quarters · filed 2013-03-01 | $217.28M derived: sum of 3 quarters · filed 2013-03-01 | $41.18M 10-K · filed 2014-02-11 |
| 2011-09-30 | $228.45M 10-K · filed 2013-03-01 | $29.13M derived: sum of 2 quarters · filed 2013-03-01 | -$146.96M 10-Q · filed 2012-11-06 | -$327.35M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | -$199.32M 10-K · filed 2013-03-01 | -$375.41M 10-Q · filed 2012-08-08 | -$555.81M derived: sum of 3 quarters · filed 2013-03-01 | -$764.76M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | -$176.10M 10-K · filed 2013-03-01 | -$356.49M derived: sum of 2 quarters · filed 2013-03-01 | -$565.45M derived: sum of 3 quarters · filed 2013-03-01 | -$765.45M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | -$180.39M 10-K · filed 2011-02-17 | -$389.35M derived: sum of 2 quarters · filed 2011-11-03 | -$589.36M derived: sum of 3 quarters · filed 2011-11-03 | -$754.63M 10-K · filed 2013-03-01 |
| 2010-09-30 | -$208.96M 10-Q · filed 2011-11-03 | -$408.96M derived: sum of 2 quarters · filed 2011-11-03 | -$574.23M 10-Q · filed 2011-11-03 | -$732.88M derived: sum of 4 quarters · filed 2011-11-03 |
| 2010-06-30 | -$200.01M 10-Q · filed 2011-08-09 | -$365.28M 10-Q · filed 2011-08-09 | -$523.92M derived: sum of 3 quarters · filed 2011-08-09 | -$673.49M derived: sum of 4 quarters · filed 2011-08-09 |
| 2010-03-31 | -$165.27M 10-Q · filed 2011-05-06 | -$323.92M derived: sum of 2 quarters · filed 2011-05-06 | -$473.48M derived: sum of 3 quarters · filed 2011-05-06 | -$644.78M derived: sum of 4 quarters · filed 2011-05-06 |
| 2009-12-31 | -$158.64M 10-K · filed 2011-02-17 | -$308.21M derived: sum of 2 quarters · filed 2011-02-17 | -$479.51M derived: sum of 3 quarters · filed 2011-02-17 | -$642.18M 10-K · filed 2012-02-22 |
| 2009-09-30 | -$149.56M 10-K · filed 2011-02-17 | -$320.86M derived: sum of 2 quarters · filed 2011-02-17 | -$483.53M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | -$171.30M 10-K · filed 2011-02-17 | -$333.97M 10-Q · filed 2010-08-03 | ||
| 2009-03-31 | -$162.67M 10-K · filed 2011-02-17 | |||
| 2008-12-31 | -$459.85M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |